21st International Prostate Cancer Update

Vail, Colorado
Wednesday, January 26, 2011

21st International Prostate Cancer Update
Wednesday, January 26, 2011 - Saturday, January 29, 2011

Cascade Conference Center
Vail, Colorado

 Overview

Patterns of care in prostate cancer have changed tremendously in the past 20 years, altering the way patients with this tumor present and how they are evaluated before and after diagnosis. With the use of new and combined treatments, the frequency and variety of complications have differed from those previously reported. Advances have been made in prostate cancer imaging, in biopsy methodology, in understanding causative factors and disease, in treatment-related quality of life, and in predicting the behavior of individual tumors using risk strata. Despite these advances, no consensus has emerged regarding the optimal treatment for the most common patient with prostate cancer.

There is a need for both oncologists and urologists to understand the rationale behind targeted therapy for the treatment of advanced prostate cancer and how trial entry could improve the efficacy of drugs and decrease the toxicity. This activity seeks to educate urologists and other healthcare professionals about the latest advances in the prevention, screening, and treatment of prostate cancer. The International Prostate Cancer Update (IPCU) educational planning committee has identified the following educational gaps between recent research in prostate cancer and its integration into professional practice at the international, national, and community levels:

  • Current guidelines in prevention and screening of prostate cancer
  • Promising therapies, issues, and economic concerns in the treatment of localized disease
  • Role of androgen deprivation therapy
  • Emerging treatments for advanced and castration-resistant prostate cancer

 Learning Objectives

This educational initiative aims to reach urologists, oncologists, and urologic oncologists. Upon completion of this activity, participants will be able to:

  • Summarize the pathology of prostate cancer and corresponding prevention and screening strategies, including PSA testing, the need for new biomarkers, and the watchful waiting option
  • Compare and contrast the use of radiation and drug therapy for the management of localized prostate cancer
  • Analyze the disease conditions that can affect bone health, including hypogonadism, androgen deprivation, and bone metastases
  • Explain the role of hormone deprivation therapy, including benefits, complications, and the therapeutic approaches to the treatment of complications
  • Identify the scientific rationale and clinical trial design of targeted agents for the treatment of advanced hormone refractory prostate cancer
  • Define recent developments in prostate cancer surgery that improve patient oncologic and quality-of-life outcomes
  • Compare and contrast the available treatment options and efficacy and safety of focal therapy
 Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Carden Jennings Publishing. MER is accredited by the ACCME to provide continuing medical education for physicians.

  Credit Designation

Medical Education Resources designates this educational activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Contact Information

Payment Instructions

  • Payment with credit card can be made via this website. If paying by check, make checks payable to Carden Jennings Publishing Co., Ltd. and addressed to:

    Carden Jennings Publishing Co., Ltd.
    375 Greenbrier Drive, Suite 100
    Charlottesville, VA 22901


    Call for Abstracts

    You are invited to submit an abstract reflecting your latest findings in the fields of prostate cancer management and prevention. Authors of accepted submissions will be invited to display a poster at the meeting, as well as give a brief oral presentation.

    Submission of Abstract

    • Please submit an abstract of 500 words or less (single-spaced, 10-point size); include a title for the abstract
    • Spell out complete names of all authors
    • List the institution, city, state, country, and e-mail address of the presenting author
    • E-mail the document to jdegraff@cjp.com

    The deadline for submitting abstracts for the 21st International Prostate Cancer Update is December 24, 2010.
© 2017
Quick, easy and affordable online event registration and event management software for all event sizes.